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www.cdatm.orgAbstractObjective: The aim of this study was to reveal the exact changes during the occurrence of breast cancer to explore significant new
and promising genes or factors related to this disease.
Methods: We compared the gene expression profiles of breast cancer tissues with its uninvolved normal breast tissues as controls
using the cDNA microarray analysis in seven breast cancer patients. Further, one representative gene, named IFI30, was quanti-
tatively analyzed by real-time PCR to confirm the result of the cDNA microarray analysis.
Results: A total of 427 genes were identified with significantly differential expression, 221 genes were up-regulated and 206 genes
were down-regulated. And the result of cDNA microarray analysis was validated by detection of IFI30 mRNA level changes by
real-time PCR. Genes for cell proliferation, cell cycle, cell division, mitosis, apoptosis, and immune response were enriched in the
up-regulated genes, while genes for cell adhesion, proteolysis, and transport were significantly enriched in the down-regulated
genes in breast cancer tissues compared with normal breast tissues by a gene ontology analysis.
Conclusion: Our present study revealed a range of differentially expressed genes between breast cancer tissues and normal breast
tissues, and provide candidate genes for further study focusing on the pathogenesis and new biomarkers for breast cancer.
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Breast cancer is the most frequent cancer among
women worldwide. As the latest WHO statistics show
that there were 1.67 million new cases diagnosed in
2012, which was 25% of all cancers.1 And breast
cancer is still the leading cause of cancer-related
death in women in less developed countries,Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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greatly improved in the past decades.2 The activation
and overexpression of oncogenes, as well as the
decreased expression or deletion of cancer suppressor
genes, have been proven to play important roles in the
development of breast cancer.3e6 Although, a large
number of studies on molecular genetics and molec-
ular biology have revealed that multiple genes and
factors take part in the pathogenesis of breast cancer,
the exact mechanism is still unclear. Therefore, there
is a huge need to identify new and promising genes or
factors which can be used as biomarkers to predict the
prognosis or sensitivity as well as the effect of treat-
ments for breast cancer.
Currently, transcriptional profiling of gene expres-
sion achieved by cDNA microarrays has greatly
increased our knowledge of the pathomechanisms
involved in various types of cancers. This high-through
put technique identifying a large number of promising
genes has been successfully used in distinguishing
subclasses of caner as well as predicting the clinical
outcome and the response to particular treatments.7,8
Thus, we choose to use the cDNA microarray tech-
nology to discover the exact changes during the
occurrence of breast cancer to look for new promising
genes or factors.
In the present study, we compared the gene
expression profiles of breast cancer tissue with its un-
involved normal breast tissue as the control using the
cDNA microarray analysis. We found that differences
existed between the two groups in gene expression
profiles. And a large number of genes were identified
that were significantly changed during the occurrence
of the disease. Furthermore, we confirmed the cDNA
microarray results by detecting one selected gene's
change of expression by the use of quantitative real-
time PCR. Thus, the cDNA microarray analysis here
provide plenty of candidate genes for further study
focusing on the pathogenesis and biomarkers of breast
cancer.Table 1
The general characteristics of the seven patients enrolled.
No Age Pathological type Histological grade
1 55 IDC II
2 41 IDC II
3 59 IDC II
4 53 IDC II
5 39 IDC II
6 57 IDC II
7 35 IDC IIMaterial and methods
Ethics statement
This study was approved by the Institutional Review
Board of the Second Hospital of Shandong University,
and written informed consent was obtained from each
patient.
Patients
The enrolled specimens were collected from
seven women patients with pathologically confirmed
invasive breast cancer in the Second Hospital of
Shandong University from May 1, 2009 to Feb 28,
2010. All the patients enrolled followed strict eligi-
bility and exclusion criteria as follows: eligibility
criteria were female, histologically confirmed inva-
sive breast ductal carcinoma without prior treatment
before surgery, patients underwent modified radical
mastectomy, having available breast cancer tissue
samples as well as normal breast tissue samples,
complete basic clinical and pathological information,
and a signed informed consent. The exclusion
criteria included prior invasive malignancy within
five years, pregnancy, receiving neoadjuvant therapy
for breast cancer, bilateral breast cancer, and having
a family history of breast cancer. The general char-
acteristics of the seven patients enrolled are shown
in Table 1.
Clinical tissue sample collections
All tumor tissues and adjacent normal tissues were
collected into liquid nitrogen within 30 min after the
resection of the mammary tissue. Pathological review
of hematoxylin and eosin-stained sections was used for
evaluation of the histological characteristics of all
specimens. All the adjacent normal breast tissues were
obtained from breast cancer patients who underwentTumor size ER PR Her-2 Ki67(%)
1.5*0.5 þþþ ±  10
3.0*2.0 þ þþþ  5
2.0*2.0 þþþ þþþ  10
1.8*1.0 þþþ þþþ  10
1.0*0.8 þþþ þþ  30
1.8*1.5 þþþ þþþ  30
2.3*1.8 þþþ þþþ  50
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referred to the region where more than 5 cm away from
the tumor sites. All samples were reevaluated inde-
pendently by two pathologists to confirm the diagnosis
and to estimate the tumor cell content. All these
enrolled cancer specimens contained at least 60
percent breast cancer cells, and all normal specimens
were pathologically confirmed as normal ductal
epithelium without atypical hyperplasia.
Gene expression microarray analyses
Total RNA was extracted from those frozen tissues
with Trizol Reagent (Invitrogen, Gaithersburg, MD,
USA) following the manufacturer's instructions. And
the RNA concentration and purity were determined
by A260 and A260/280 ratio through ultraviolet
spectrophotometer (Nanodrop, ND-1000), and further
checked by electrophoresis. The human long oligonu-
cleotide microarray used in the present study was
constructed by CapitalBio Corporation (Beijing,
China). The microarray genechip consists of 50-amino-
modified 70-mer probes represented 35,035 well-
characterized human genes. The P value for signifi-
cance cutoff was 0.05. This experimental protocol has
been described previously.9
Real-time RT-PCR assay
Total RNAwas extracted by TRIzol according to the
manufacturer's protocol. Total RNA was dissolved in
nuclease-free water. All RNAs were verified for purity
as well as concentration by NanoDrop analysis. After
genomic DNAwas digested by DNase I and the residual
RNA was purified, all the RNA was reverse-transcribed
in a final volume of 20 ml using Superscript II (Invi-
trogen, USA) according to the manufacturer's protocol.
Quantitative analysis of IFI30 mRNA expression was
performed in paired breast cancer tissues and normal
breast tissues by using the 7900 HT Fast RealTime PCR
system (Applied Biosystems, USA). IFI30 was
amplified with the following primers: 50-ATGTCAC
GCTGGTGCCCTAC-30 (forward primer) and 50-GTCA
AGTTCATCCAACACGCA-30 (reverse primer). ACTB
was used as an endogenous control with the following
primers: 50-CATGTACGTTGCTATCCAGGC-30 (for-
ward primer) and 50-CTCCTTAATGTCACGCAC
GAT-30 (reverse primer). The results were evaluated
by the comparative threshold cycle value method
(2DDct). Each RT-qPCR experiment was repeated three
times.Results
Genes differentially expressed between breast cancer
tissues and normal breast tissues
To identify candidate genes which may contribute to
the pathogenesis of breast cancer, gene expression
profiles of breast cancer tissues and normal breast tis-
sues were comparatively analyzed by the cDNA
microarray technique. A total of 427 genes were
screened as differently expressed in breast cancer tis-
sues compared with normal breast tissues at significant
levels (P < 0.05). They included 221 up-regulated
genes and 206 down-regulated genes. Among these
differentially expressed genes, 36 genes were up-
regulated >5-fold; such as PTTG1, CDC2,
KIAA0101, DLG7, NUF2, S100P, TPX2, and IFI30.
Different gene expression profiles between breast
cancer tissues and normal breast tissues
In order to clarify the different gene expression
profiles between breast cancer tissues and normal
breast tissues, we conducted cluster analysis of 14
tissue samples based on the detected genes. The result
is shown in Fig. 1. The gene expression profiles of
breast cancer samples were partly distinguished from
the normal breast tissues, indicating that differences
existed between the two groups.
Functional classification of the differentially
expressed genes
To explore candidate biological pathways which
may contribute to the pathogenesis of breast cancer, we
performed a hierarchical clustering followed by a gene
ontology (GO) analysis on the differentially expressed
genes. The GO analysis of the differentially expressed
genes was based on molecular function as well as
biological processes and revealed a number of distinct
functional groups. Cell proliferation, cell cycle, cell
division, mitosis, apoptosis, and immune response
genes were enriched in the up-regulated genes, while
cell adhesion, proteolysis, and transport genes were
significantly enriched in the down-regulated genes in
breast cancer tissues compared with normal breast
tissues. Several representative and important biological
processes, including a large number of related differ-
entially expressed genes shown in Tables 2e5, are
involved in immune function, cell proliferation, cell
adhesion, and apoptosis.
Fig. 1. Cluster analysis results for gene expression in breast cancer tissues and normal breast tissues. The expression values clustered in the red-
shaded areas indicate up-regulation, and the green-shaded areas indicate down-regulation. The abbreviations in the figure were as follows: BC, for
breast cancer tissues and NC, for normal breast tissues.
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To confirm the result of the cDNA microarray anal-
ysis, one representative gene, IFI30, was quantitatively
analyzed by real-time PCR. This gene was selected for
three reasons as follows: 1) it was up-regulated with a
high fold-change at a significant level, 2) it appeared inTable 2
Differential expressed genes related to immune function.
Accession Gene symbol Description
NM_006332 IFI30 Gamma-interferon-inducible lysosomal th
NM_130398 EXO1 Exonuclease 1
NM_005101 ISG15 Interferon-induced 17 kDa protein precur
NM_002351 SH2D1A SH2 domain-containing protein 1A
NM_005514 HLA-B HLA class I histocompatibility antigen
NM_003467 CXCR4 C-X-C chemokine receptor type 4
NM_022873 IFI6 Interferon-induced protein 6-16 precurso
NM_000593 TAP1 Antigen peptide transporter 1
NM_002117 HLA-C HLA class I histocompatibility antigen
NM_004335 BST2 Bone marrow stromal antigen 2 precurso
NM_015932 POMP Proteasome maturation protein
NM_000569 FCGR3A Low affinity immunoglobulin gamma Fc
NM_148170 CTSC Cathepsin C
NM_006847 LILRB4 Leukocyte immunoglobulin-like receptor
NM_005533 IFI35 Interferon-induced 35 kDa protein
NM_004048 B2M Beta-2-microglobulin precursor
NM_004031 IRF7 Interferon regulatory factor 7
NM_002996 CX3CL1 Fractalkine precursor
NM_181524 PIK3R1 Phosphatidylinositol 3-kinase regulatory
NM_199168 CXCL12 chemokine (C-X-C motif) ligand 12both functional classification and clustering analysis, 3)
it presented a promising function by the current research
findings in cancer pathogenesis as it is related to cancer
immunity, in which we were interested. As shown in
Fig. 2, real-time PCR results confirmed IFI30 mRNA
was increased significantly in breast cancer tissues
compared with the corresponding adjacent normalChange Fold
change
P value
iol reductase precursor [ 5.4016 <0.001
[ 3.3573 <0.001
sor [ 7.4359 <0.001
[ 6.3158 <0.001
[ 2.2504 0.0057
[ 2.3894 0.0057
r [ 2.6298 0.0069
[ 3.6752 0.0125
[ 2.0259 0.0167
r [ 4.3109 0.0200
[ 2.1079 0.0209
[ 2.2588 0.0267
[ 2.7163 0.0267
subfamily B member 4 precursor [ 2.2951 0.0301
[ 3.5268 0.0328
[ 2.0588 0.0328
[ 2.3360 0.0414
Y 0.3260 0.0141
subunit alpha Y 0.4631 0.0167
Y 0.4500 0.0210
Table 3
Differential expressed genes related to cell proliferation.
Accession Gene symbol Description Change Fold change P value
NM_005192 CDKN3 Cyclin-dependent kinase inhibitor 3 [ 5.1270 <0.001
NM_001311 CRIP1 Cysteine-rich protein [ 3.7188 <0.001
NM_012112 TPX2 Targeting protein for Xklp2 [ 9.6235 <0.001
NM_002351 CKS2 Cyclin-dependent kinases regulatory subunit 2 [ 5.0202 <0.001
NM_006845 KIF2C Kinesin-like protein KIF2C [ 3.9517 <0.001
NM_003467 CXCR4 C-X-C chemokine receptor type 4 [ 2.3894 0.0057
NM_005030 PLK1 Serine/threonine-protein kinase PLK1 [ 2.6298 0.0069
NM_021173 POLD4 DNA polymerase subunit delta 4 [ 2.1277 0.0110
NM_003318 TTK Dual specificity protein kinase TTK [ 4.9328 0.0110
NM_012346 NUP62 Nucleoporin 62 kDa [ 2.0221 0.0125
NM_004336 BUB1 Mitotic checkpoint serine/threonine-protein kinase BUB1 [ 7.5387 0.0125
NM_007045 FGFR1OP FGFR1 oncogene partner [ 2.4699 0.0125
NM_033285 TP53INP1 Tumor protein p53-inducible nuclear protein 1 [ 2.2895 0.0125
NM_016343 CENPF Centromere protein F [ 5.0906 0.0166
NM_004335 BST2 Bone marrow stromal antigen 2 precursor [ 4.3109 0.0200
NM_005727 TSPAN1 Tetraspanin-1 [ 3.3838 0.0210
NM_003225 TFF1 Trefoil factor 1 precursor [ 6.4284 0.0210
NM_004494 HDGF Hepatoma-derived growth facto [ 2.0478 0.0301
NM_014750 DLG7 Discs large homolog 7 [ 9.9318 0.0327
NM_003503 CDC7 Cell division cycle 7-related protein kinase [ 2.3667 0.0327
NM_017548 CDV3 CDV3 homolog [ 2.3609 0.0414
NM_004585 RARRES3 Retinoic acid receptor responder protein 3 [ 2.2753 0.0498
NM_006533 MIA Melanoma-derived growth regulatory protein precursor Y 0.3528 0.0141
NM_003888 ALDH1A2 Retinal dehydrogenase 2 Y 0.4265 0.0141
NM_002178 IGFBP6 Insulin-like growth factor-binding protein 6 precursor Y 0.3603 0.0142
NM_001145 ANG Ribonuclease 4 precursor Y 0.4966 0.0200
NM_000612 IGF2 Insulin-like growth factor II precursor Y 0.4022 0.0210
NM_005228 EGFR Epidermal growth factor receptor precursor Y 0.4726 0.0448
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with the result from cDNA microarray analysis.
Discussion
In the present study, we have revealed differentially
expressed genes in breast cancer compared withTable 4
Differential expressed genes related to cell adhesion.
Accession Gene symbol Description
NM_002026 FN1 Fibronectin precursor
NM_130398 LPXN Leupaxin
NM_005727 TSPAN1 Tetraspanin-1
NM_016639 TNFRSF12A Tumor necrosis factor receptor superfam
NM_006288 THY1 Thy-1 membrane glycoprotein precursor
NM_001670 ARVCF Armadillo repeat protein deleted in velo
NM_002996 CX3CL1 Fractalkine precursor
NM_005168 RND3 Rho-related GTP-binding protein RhoE
NM_006329 FBLN5 Fibulin-5 precursor
NM_000228 LAMB3 Laminin subunit beta-3 precursor
NM_199168 CXCL12 Stromal cell-derived factor 1 precursor
NM_002404 MFAP4 Microfibril-associated glycoprotein 4 pre
NM_033254 BOC Brother of CDO precursor
NM_001937 DPT Dermatopontin precursoruninvolved normal control tissue by using the cDNA
microarray analysis of the gene expression profiles. A
total of 427 genes were identified with significantly
differential expression, 221 genes were up-regulated
and 206 genes were down-regulated. Multiple biolog-
ical processes were found by GO analysis in which
these differentially expressed genes took part in. CellChange Fold change P value
[ 4.5627 <0.001
[ 2.1309 0.0210
[ 3.3838 0.0210
ily member 12A precursor [ 2.5041 0.0267
[ 2.4001 0.0448
-cardio-facial syndrome Y 0.4794 0.0141
Y 0.3260 0.0141
Y 0.3721 0.0142
Y 0.4262 0.0200
Y 0.4043 0.0200
Y 0.4500 0.0210
cursor Y 0.4093 0.0301
Y 0.4480 0.0301
Y 0.4719 0.0301
Table 5
Differential expressed genes related to apoptosis.
Accession Gene symbol Description Change Fold change P value
NM_013258 PYCARD Apoptosis-associated speck-like protein containing a CARD [ 2.6746 <0.001
NM_004324 BAX BAX protein [ 2.1953 <0.001
NM_001908 CTSB Cathepsin B precursor [ 2.0506 0.0069
NM_021127 PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 [ 4.3945 0.0069
NM_014397 NEK6 Serine/threonine-protein kinase Nek6 [ 2.0326 0.0069
NM_001168 BIRC5 Baculoviral IAP repeat-containing protein 5 [ 6.7460 0.0069
NM_002192 INHBA Inhibin beta A chain precursor [ 3.3210 0.0125
NM_012346 NUP62 L-amino-acid oxidase precursor [ 2.0221 0.0125
NM_033379 CDC2 Cell division control protein 2 homolog [ 13.5476 0.0125
NM_033285 TP53INP1 Tumor protein p53-inducible nuclear protein 1 [ 2.2895 0.0125
NM_002466 MYBL2 Myb-related protein B [ 7.5657 0.0142
NM_022073 EGLN3 Egl nine homolog 3 [ 2.6077 0.0200
NM_005356 LCK Proto-oncogene tyrosine-protein kinase LCK [ 4.8360 0.0210
NM_016639 TNFRSF12A Tumor necrosis factor receptor superfamily member 12A precursor [ 2.5041 0.0267
NM_006904 PRKDC DNA-dependent protein kinase catalytic subunit [ 2.0768 0.0301
NM_000041 APOE Apolipoprotein E precursor [ 2.2342 0.0301
NM_016640 MRPS30 Mitochondrial 28S ribosomal protein S30 [ 6.1910 0.0414
NM_006288 THY1 Thy-1 membrane glycoprotein precursor [ 2.4001 0.0448
NM_003012 SFRP1 Secreted frizzled-related protein 1 precursor Y 0.2201 0.0141
NM_181524 PIK3R1 Phosphatidylinositol 3-kinase regulatory subunit alpha Y 0.4631 0.0166
NM_016109 ANGPTL4 Angiopoietin-related protein 4 precursor Y 0.4228 0.0210
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apoptosis, and immune response genes were enriched
in the up-regulated genes, while cell adhesion, prote-
olysis, and transport genes were significantly enriched
in the down-regulated genes in breast cancer tissues
compared with normal breast tissues.
Cell proliferation, cell cycle, cell division, apoptosis,
immune response, and cell adhesion have all been
demonstrated to be closely associated with cancers.10,11
Many oncogenes and tumor suppressors involved in
these key processes have been found to contribute to theFig. 2. Validation of the differentially expressed genes by IFI30
detected through quantitative real-time PCR. Relative means ± SD
for IFI30 mRNA. IFI30 mRNA increased significantly in breast
cancer tissues compared with the corresponding adjacent normal
breast tissues (*P ¼ 0.009), which was in accordance with the result
from cDNA microarray analysis.occurrence aswell as development ofmalignant diseases.
CXCR4, a 352-amino acid rhodopsin-like G protein-
coupled receptor (GPCR), which can selectively bind
to the CXC chemokine stromal cell-derived factor 1
(SDF-1), has been identified in a large number of studies
to play a central role in cancer proliferation, invasion, and
dissemination in a majority of cancers.12 It has been
established that CXCR4 plays a significant role in
tumorigenesis as well as the progression of malignant
diseases,13 especially breast cancer.14 As reported, at
least 23 different cancers express CXCR4,15 including
breast cancer,16 prostate cancer, ovarian cancer, and
melanoma.17 In addition, the CXCR4 is highly expressed
in breast cancer, while present at low levels or absent in
normal breast tissues.16 This is consistent with the results
of our cDNA microarray analysis. Additionally, the
ligand of CXCR4, CXCL12, also known as SDF-1, was
found to be significantly down-regulated in breast cancer
tissues compared with normal breast samples. Our result
is in accordance with what has been identified by many
studies. The reduced expression of CXCL12 in breast
cancer has been associated with aggressive behavior of
breast cancer, which shows that it plays critical roles in
progression, metastasis, and prognosis of the disease.18,19
In conclusion, our findings in the present study do
identify some significant factors related to breast cancer
which have been demonstrated in previous studies.
Additionally, IFI30, one of the most significantly
increased genes in breast cancer tissues in our study, is a
71Y.-J. Xiang et al. / Chronic Diseases and Translational Medicine 1 (2015) 65e72unique member of the thiol reductase family because of
its optimal pH being 4.5e5.5,20e22 and it is the only one
localized in lysosomes and phagosomes.23 It has been
demonstrated that the IFI30 protein is constitutively
expressed in professional APC and plays important roles
in the process of exogenous antigen processing as well
as presentation,24 moreover affects the anti-tumor im-
munity.25 This gene is a newly found tumor suppressor
gene with a promising future as a target in malignant
disease treatment and the effects of this gene have been
identified in several cancers, including melanomas,26
diffuse large B-Cell lymphoma,27 prostate cancer,28
and glioblastoma.29 Furthermore, we have confirmed
that the absence of GILT expression in primary breast
cancer was independently associated with poor disease-
free survival of patients.9
However, there are some deficiencies in our study.
The samples we used in this cDNA microarray analysis
were breast cancer tissues and uninvolved normal
breast tissues. They contain a mixture of different cell
types, which may influence the exact changes found in
our work. But, we have previously demonstrated the
changes in IFI30 expression by laser-capture micro-
dissection (LCM) to obtain a relatively pure population
of epithelial cells and neoplastic cells from uninvolved
breast tissues and breast cancer tissues for mRNA
evaluation.9 The validation of differentially expressed
genes by quantitative real-time PCR was done with
only one gene in our study, and the number of genes
needs to be extended to include more genes in the
future. Altogether, we think that most of the differen-
tially expressed genes found in our present work
worthy of further study to uncover their potential ef-
fects in breast cancer.
Conclusions
Our present study revealed a range of differentially
expressed genes by comparing the gene expression
profiles of breast cancer tissues with uninvolved
normal control breast tissue. Most of these genes have
the potential to play critical roles in the pathogenesis or
development of breast cancer according to the func-
tional analysis. Thus, we provide candidate genes for
further research to explore potential biomarkers or
therapeutic targets in this disease.
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